Anti-hEGFR-hIgG1
-
Cat.code:
hegfr-mab1
- Documents
ABOUT
EGFR Inhibitor - Cetuximab biosimilar - CAS #205923-56-4
Anti-hEGFR-hIgG1 is a biosimilar research antibody to Cetuximab. Cetuximab (C225, IMC-C225) is a chimeric human/mouse IgG1κ antibody targeting the epidermal growth factor receptor (EGFR). This monoclonal antibody (mAb) is FDA-approved for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck.
Anti-hEGFR-hIgG1 comprises the variable region and a human IgG1 constant region mediating high effector functions.
This antibody can be used together with HEK-Blue™ EGF cells for screening and neutralization assays to block signaling induced by recombinant human EGF (see figures). It can also be used together with the human EGFR-expressing Raji target cell line for ADCC Fc effector studies*, either with peripheral blood mononuclear cells, natural killer (NK) cells, or T cell-derived Jurkat reporter cells (see figures).
Key features
- Each lot is functionally tested and validated.
- The complete sequence of the antibody construct was verified.
- The absence of endotoxins is determined by the EndotoxDetect™ assay.
* More isotypes of this antibody are available and can be used for comparison of biological activities such as ADCC (see in the 'upon request' section).
All InvivoGen products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
EGFR
Human
Neutralization assay (tested)
Flow cytometry (tested)
ADCC assay (tested)
ELISA
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
0.22 µm filtration
Negative (tested using EndotoxDetect™ assay)
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hEGFR-hIgG1
-
Cat code:hegfr-mab1
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Cetuximab background
Cetuximab (ERBITUX®) is a chimeric mouse/human IgG1 monoclonal antibody (mAb) that specifically targets the epidermal growth factor receptor (EGFR). EGFR is a cell surface receptor overexpressed in many types of cancer, promoting cancer cell proliferation, survival, and angiogenesis, subsequently leading to tumor growth and metastasis [1].
Cetuximab binds to the extracellular domain III of EGFR, blocking ligand interaction and preventing receptor dimerization and activation triggered by its natural ligands, such as epidermal growth factor (EGF), transforming growth factor-α (TGF-α), amphiregulin, and heparin-binding EGF (HB-EGF) [2]. Due to its IgG1 constant region, it also induces receptor internalization, degradation, and cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) [3-4]. Cetuximab is FDA-approved for a variety of cancer types, such as squamous cell carcinoma of the head and neck (SCCHN) and colorectal cancer [5].
References:
1. Vincenzi B. et al., 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 10(1):80-95.
2. Li S, Schmitz KR, et al., 2005. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 7(4):301-11.
3. Kurai J. et al., 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 3(5):1552-61.
4. Kimura H. et al., 2007. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8):1275-80.
5. FDA website accessed in Jan 2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz